APUS: Inscobee, Apimeds Boost Stakes, Seek Board Changes

This filing is an amendment to a Schedule 13D by Inscobee Inc. and Apimeds Inc. regarding their ownership of Apimeds Pharmaceuticals US, Inc. (APUS) common stock. The filing indicates that as of March 20, 2026, Inscobee Inc. beneficially owns 2,099,747 shares, representing 16.7% of the outstanding stock, and Apimeds Inc. beneficially owns 4,316,618 shares, representing 34.3%. This increase in ownership and voting power has led to significant corporate actions. The reporting persons, along with other majority stockholders, have executed an Action by Written Consent to amend the company's bylaws. These amendments empower stockholders to fill board vacancies and approve bylaw changes with a majority vote. Furthermore, the existing board of directors has been removed, and three new members have been appointed to fill the vacancies. The new board is expected to review the company's merger with MindWave Innovations Inc., investigate potential financial irregularities, and explore new business initiatives, including expansion into Korean markets. The reporting persons reserve the right to pursue further corporate actions, including potential litigation.